Please assess the completion status of the following clinical trial:

Trial Title: Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary participation in the study with signature on Informed Consent Form (ICF) prior to specific protocol procedures~* Patients of any race~* On outpatient treatment~* History of frequent symptom crises related to GERD within the last 3 months (at least a frequency of twice a week, for about four to eight weeks)~* Diagnosis of erosive esophagitis (grade A to D, according to Los Angeles Classification)~* In good health condition, except GERD symptoms~* Able to follow the protocol directions and to complete daily the questionnaire ReQuest™ throughout the study~Exclusion Criteria:~* Gastrointestinal disorder, even when related to chlorhydropeptic disorders: Barret's esophagus, peptic ulcer, Zollinger-Ellison syndrome and pyloric stenosis~* Previous history of surgery to reduce acid secretion, or other upper gastrointestinal tract surgeries (excepting polypectomy and cholecystectomy)~* At initial endoscopy presenting complicated disorders due to erosive esophagitis: obstructive esophageal stenoses, Schatzki ring, esophageal diverticulum, esophageal varices, achalasia and hiatal hernia~* Pregnant women or during nursing period~* Proton Pump Inhibitors (PPIs) within the last 10 days prior to start of the study~* Triple therapy based on PPIs to eradicate H. pylori within the last 28 days prior to start of the study~* H2-blockers, sucralfate and prokinetics within the last 7 days prior to start of the study~* Systemic glucocorticoids and/or nonsteroidal anti-inflammatory drugs (including COX-2 inhibitors) for more than 3 consecutive days a week, within the last 28 days prior to start of study, with exception of regular intake of acetyl salicylic acid in dosages of up to 163 mg/day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Magnesium Pantoprazole (Type: ACTIVE_COMPARATOR): None
- Magnesium Esomeprazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).